BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection

PLoS ONE

Volumn 13, Issue 5, 2018, Pages

  Solbach, Philipp ^a,b   Chhatwal, Patrick ^a,b   Woltemate, Sabrina ^a,b   Tacconelli, Evelina ^c,d   Buhl, Michael ^c,d   Gerhard, Markus ^e,f   Thoeringer, Christoph K ^f,g   Vehreschild, Maria J G T ^h,i   Jazmati, Nathalie ^i,j   Rupp, Jan ^k,l   Manns, Michael P ^a   Bachmann, Oliver ^a,b   Suerbaum, Sebastian ^a,b,f,m  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d German Center for Research in Infectious Disease (DZIF)   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f German Center for Infection Research   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ German Center for Infection Research   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l German Center for Infection Research (DZIF)   (Germany)

^m UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BAICD GENE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FEMALE; GENE CLUSTER; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PREVALENCE; QUANTITATIVE ANALYSIS; RECURRENT INFECTION; BILE; BIOSYNTHESIS; CLOSTRIDIUM INFECTION; DIARRHEA; FECES; GENETICS; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; TRANSMISSION;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; BILE ACID;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BILE; BILE ACIDS AND SALTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; MALE; MICROBIOTA;

EID: 85046658322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0196977     Document Type: Article

References (79)

1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. The New England journal of medicine. 2014; 370 (13):1198–208. https://doi.org/10.1056/NEJMoa1306801 PMID: 24670166
2. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable Burden of Hospital-Onset Clostridium difficile Infection: A Propensity Score Matching Study. Infection Control & Hospital Epidemiology. 2013; 34(06):588–96.
3. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. The Journal of hospital infection. 2012; 81(1):1–14. https://doi.org/10.1016/j.jhin.2012.02.004 PMID: 22498638
4. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends in microbiology. 2012; 20(7):313–9. https://doi.org/10.1016/j.tim.2012.04. 001 PMID: 22595318
5. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014; 146(6):1547–53. https://doi.org/10.1053/j.gastro.2014.01.059 PMID: 24503131
6. Yurist-Doutsch S, Arrieta MC, Vogt SL, Finlay BB. Gastrointestinal microbiota-mediated control of enteric pathogens. Annual review of genetics. 2014; 48:361–82. https://doi.org/10.1146/annurev-genet-120213-092421 PMID: 25251855
7. May T, Mackie RI, Fahey GC Jr., Cremin JC, Garleb KA. Effect of fiber source on short-chain fatty acid production and on the growth and toxin production by Clostridium difficile. Scandinavian journal of gastroenterology. 1994; 29(10):916–22. PMID: 7839098
8. Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Current opinion in gastroenterology. 2018; 34(1):3–10. https://doi.org/10.1097/MOG.0000000000000410 PMID: 29189354
9. Rolfe RD. Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infection and immunity. 1984; 45(1):185–91. PMID: 6735467
10. Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. Anaerobe. 2017; 45:86–100. https://doi.org/10.1016/j.anaerobe.2017.03.004 PMID: 28279860
11. Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: discrimination of pathogenic and non-pathogenic microbes by the innate immune system. Cell host & microbe. 2009; 6(1):10–21.
12. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. Journal of bacteriology. 2008; 190(7):2505–12. https://doi.org/10.1128/JB.01765-07 PMID: 18245298
13. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. Journal of bacteriology. 2010; 192(19):4983–90. https://doi.org/10.1128/JB.00610-10 PMID: 20675492
14. Francis MB, Allen CA, Shrestha R, Sorg JA. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS pathogens. 2013; 9(5):e1003356. https://doi.org/10.1371/journal.ppat.1003356 PMID: 23675301
15. Kitahara M, Takamine F, Imamura T, Benno Y. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces. International journal of systematic and evolutionary microbiology. 2000; 50 Pt 3:971–8.
16. Kitahara M, Takamine F, Imamura T, Benno Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity. International journal of systematic and evolutionary microbiology. 2001; 51(Pt 1):39–44. https://doi.org/10.1099/00207713-51-1-39 PMID: 11211270
17. Wells JE, Berr F, Thomas LA, Dowling RH, Hylemon PB. Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients. Journal of hepatology. 2000; 32(1):4–10. PMID: 10673060
18. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut microbes. 2016; 7(1):22–39. https://doi.org/10.1080/19490976.2015. 1127483 PMID: 26939849
19. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. Journal of lipid research. 2006; 47(2):241–59. https://doi.org/10.1194/jlr.R500013-JLR200 PMID: 16299351
20. Baron SF H P. Biotransformation of bile acids, cholesterol, and steroid hormones. Mackie RL W B, editor. Gastrointestinal microbiology: Chapman and Hall; 1996.
21. Wells JE, Hylemon PB. Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. Applied and environmental microbiology. 2000; 66(3):1107–13. PMID: 10698778
22. Kang DJ, Ridlon JM, Moore DR, Barnes S, Hylemon PB. Clostridium scindens baiCD and baiH genes encode stereo-specific 7alpha/7beta-hydroxy-3-oxo-delta4-cholenoic acid oxidoreductases. Biochimica et biophysica acta. 2008; 1781(1–2):16–25. https://doi.org/10.1016/j.bbalip.2007.10.008 PMID: 18047844
23. Berr F, Kullak-Ublick GA, Paumgartner G, Munzing W, Hylemon PB. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology. 1996; 111(6):1611–20. PMID: 8942741
24. Doerner KC, Takamine F, LaVoie CP, Mallonee DH, Hylemon PB. Assessment of fecal bacteria with bile acid 7 alpha-dehydroxylating activity for the presence of bai-like genes. Applied and environmental microbiology. 1997; 63(3):1185–8. PMID: 9055436
25. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut microbes. 2013; 4(5):382–7. https://doi.org/10.4161/gmic.25723 PMID: 23851335
26. Carman RJ, Simon MA, Petzold HE, Wimmer RF, Batra MR, Fernandez AH, et al. Antibiotics in the human food chain: establishing no effect levels of tetracycline, neomycin, and erythromycin using a che-mostat model of the human colonic microflora. Regulatory toxicology and pharmacology: RTP. 2005; 43(2):168–80. https://doi.org/10.1016/j.yrtph.2005.06.005 PMID: 16129531
27. Giel JL, Sorg JA, Sonenshein AL, Zhu J. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PloS one. 2010; 5(1):e8740. https://doi.org/10.1371/journal.pone.0008740PMID: 20090901
28. Hashimoto S, Igimi H, Uchida K, Satoh T, Benno Y, Takeuchi N. Effects of beta-lactam antibiotics on intestinal microflora and bile acid metabolism in rats. Lipids. 1996; 31(6):601–9. PMID: 8784740
29. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, et al. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid-producing intestinal flora. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan. 2009; 129(5):601–8. PMID: 19420891
30. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015; 517(7533):205–8. https://doi.org/10.1038/nature13828 PMID: 25337874
31. Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014; 20 Suppl 2:1–26.
32. Snell H, Ramos M, Longo S, John M, Hussain Z. Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. Journal of clinical microbiology. 2004; 42(10):4863–5. https://doi.org/10.1128/JCM.42.10.4863-4865. 2004 PMID: 15472364
33. Zheng L, Keller SF, Lyerly DM, Carman RJ, Genheimer CW, Gleaves CA, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. Journal of clinical microbiology. 2004; 42(8):3837–40. https://doi.org/10.1128/JCM.42.8.3837-3840.2004 PMID: 15297543
34. Berry N, Sewell B, Jafri S, Puli C, Vagia S, Lewis AM, et al. Real-time polymerase chain reaction correlates well with clinical diagnosis of Clostridium difficile infection. The Journal of hospital infection. 2014; 87(2):109–14. https://doi.org/10.1016/j.jhin.2014.03.005 PMID: 24795170
35. Guerrero DM, Becker JC, Eckstein EC, Kundrapu S, Deshpande A, Sethi AK, et al. Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. The Journal of hospital infection. 2013; 85(2):155–8. https://doi.org/10.1016/j.jhin.2013.07.002 PMID: 23954113
36. Jensen MB, Olsen KE, Nielsen XC, Hoegh AM, Dessau RB, Atlung T, et al. Diagnosis of Clostridium difficile: real-time PCR detection of toxin genes in faecal samples is more sensitive compared to toxigenic culture. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2015; 34(4):727–36.
37. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. The New England journal of medicine. 2000; 342(6):390–7. https://doi.org/10.1056/NEJM200002103420604 PMID: 10666429
38. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. The New England journal of medicine. 1989; 320(4):204–10. https://doi.org/10.1056/ NEJM198901263200402 PMID: 2911306
39. Nissle K, Kopf D, Rosler A. Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients. BMC geriatrics. 2016; 16(1):185. https://doi.org/10.1186/s12877-016-0358-3 PMID: 27846818
40. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998; 351(9103):633–6. https://doi.org/10.1016/S0140-6736(97)08062-8 PMID: 9500319
41. Soh YS, Yang JJ, You E, La Jeon Y, Kim MJ, Nam YS, et al. Comparison of two molecular methods for detecting toxigenic Clostridium difficile. Annals of clinical and laboratory science. 2014; 44(1):27–31. PMID: 24695470
42. Houser BA, Hattel AL, Jayarao BM. Real-time multiplex polymerase chain reaction assay for rapid detection of Clostridium difficile toxin-encoding strains. Foodborne pathogens and disease. 2010; 7 (6):719–26. https://doi.org/10.1089/fpd.2009.0483 PMID: 20113206
43. van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, Endtz HP, van der Vorm ER, Kuijper EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. Journal of clinical microbiology. 2005; 43(10):5338–40. https://doi.org/10.1128/JCM.43.10.5338-5340.2005 PMID: 16208012
44. QIAGEN UsM. QIAamp DNA Mini and Blood Mini Handbook 2016. https://www.qiagen.com/us/resources/resourcedetail?id=62a200d6-faf4-469b-b50f-2b59cf738962&lang=en. last access: 12.02.2018
45. Ou J, Carbonero F, Zoetendal EG, DeLany JP, Wang M, Newton K, et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. The American journal of clinical nutrition. 2013; 98(1):111–20. https://doi.org/10.3945/ajcn.112.056689 PMID: 23719549
46. Mallonee DH, White WB, Hylemon PB. Cloning and sequencing of a bile acid-inducible operon from Eubacterium sp. strain VPI 12708. Journal of bacteriology. 1990; 172(12):7011–9. PMID: 2254270
47. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome research. 1996; 6(10):986–94. PMID: 8908518
48. Buckwalter SP, Sloan LM, Cunningham SA, Espy MJ, Uhl JR, Jones MF, et al. Inhibition controls for qualitative real-time PCR assays: are they necessary for all specimen matrices? Journal of clinical microbiology. 2014; 52(6):2139–43. https://doi.org/10.1128/JCM.03389-13 PMID: 24740078
49. Hartman LJ, Coyne SR, Norwood DA. Development of a novel internal positive control for Taqman based assays. Molecular and cellular probes. 2005; 19(1):51–9. https://doi.org/10.1016/j.mcp.2004.07. 006 PMID: 15652220
50. Rosenstraus M, Wang Z, Chang SY, DeBonville D, Spadoro JP. An internal control for routine diagnostic PCR: design, properties, and effect on clinical performance. Journal of clinical microbiology. 1998; 36(1):191–7. PMID: 9431945
51. QIAGEN UsM. QIAamp DNA Mini and Blood Mini Handbook; Appendix D: Protocols for Bacteria 2016 [cited April]. https://www.qiagen.com/us/resources/resourcedetail?id=62a200d6-faf4-469b-b50f2b59cf738962&lang=en. last access: 12.02.2018
52. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian journal of gastroenterology. 1997; 32(9):920–4. https://doi.org/10.3109/00365529709011203 PMID: 9299672
53. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology. 2002; 148(Pt 1):257–66. https://doi.org/10.1099/00221287-148-1-257 PMID: 11782518
54. Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflammatory bowel diseases. 2015; 21(7):1600–6. https://doi.org/10.1097/MIB.0000000000000405 PMID: 26070003
55. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. Journal of clinical gastroenterology. 2014; 48(8):693–702. https://doi.org/10.1097/MCG.0000000000000046 PMID: 24440934
56. Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017.
57. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England journal of medicine. 2013; 368(5):407–15. https://doi.org/10.1056/NEJMoa1205037 PMID: 23323867
58. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, Finlay BB. Effect of antibiotic treatment on the intestinal metabolome. Antimicrobial agents and chemotherapy. 2011; 55(4):1494–503. https://doi.org/10.1128/AAC.01664-10 PMID: 21282433
59. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS microbiology reviews. 2005; 29(4):625–51. https://doi.org/10.1016/j.femsre.2004.09.003 PMID: 16102595
60. Theriot CM, Bowman AA, Young VB. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. mSphere. 2016; 1(1).
61. Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, et al. Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. PloS one. 2016; 11(1):e0147210. https://doi.org/10.1371/journal.pone.0147210 PMID: 26789728
62. Kitahara M, Sakamoto M, Benno Y. PCR detection method of Clostridium scindens and C. hiranonis in human fecal samples. Microbiology and immunology. 2001; 45(3):263–6. PMID: 11345537
63. Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, et al. Functional Intestinal Bile Acid 7alpha-Dehydroxylation by Clostridium scindens Associated with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model. Frontiers in cellular and infection microbiology. 2016; 6:191. https://doi.org/10.3389/fcimb.2016.00191 PMID: 28066726
64. Ferrari A, Beretta L. Activity on bile acids of a Clostridium bifermentans cell-free extract. FEBS letters. 1977; 75(1):163–5. PMID: 852578
65. Stellwag EJ, Hylemon PB. Characterization of 7-alpha-dehydroxylase in Clostridium leptum. The American journal of clinical nutrition. 1978; 31(10 Suppl):S243–S7. PMID: 707382
66. Hill MJ, Drasar BS, Williams RE, Meade TW, Cox AG, Simpson JE, et al. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet. 1975; 1(7906):535–9. PMID: 47015
67. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. European journal of cancer. 1995; 31A(7–8):1067–70. PMID: 7576993
68. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut pathogens. 2010; 2(1):19. https://doi.org/10.1186/1757-4749-2-19 PMID: 21143915
69. Pop M, Paulson JN, Chakraborty S, Astrovskaya I, Lindsay BR, Li S, et al. Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent cipro-floxacin treatment. BMC genomics. 2016; 17:440. https://doi.org/10.1186/s12864-016-2777-0 PMID: 27277524
70. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016; 65(1):57–62. https://doi.org/10.1136/gutjnl-2015-309618 PMID: 26069274
71. Vetrovsky T, Baldrian P. The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PloS one. 2013; 8(2):e57923. https://doi.org/10.1371/journal.pone.0057923 PMID: 23460914
72. Tigchelaar EF, Bonder MJ, Jankipersadsing SA, Fu J, Wijmenga C, Zhernakova A. Gut microbiota composition associated with stool consistency. Gut. 2016; 65(3):540–2. https://doi.org/10.1136/gutjnl-2015-310328 PMID: 26276682
73. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. American journal of physiology Gastrointestinal and liver physiology. 2014; 306(4):G310–9. https://doi.org/10.1152/ajpgi.00282. 2013 PMID: 24284963
74. Weingarden A, Gonzalez A, Vazquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3:10. https://doi.org/10.1186/s40168-015-0070-0 PMID: 25825673
75. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. Journal of clinical gastroenterology. 2010; 44(5):354–60. https://doi.org/10.1097/MCG.0b013e3181c87e02 PMID: 20048681
76. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, et al. Administration of spores of non-toxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. Jama. 2015; 313(17):1719–27. https://doi.org/10.1001/jama.2015.3725 PMID: 25942722
77. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013; 1(1):3. https://doi.org/10.1186/2049-2618-1-3 PMID: 24467987
78. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS pathogens. 2012; 8(10):e1002995. https://doi.org/10.1371/journal.ppat.1002995PMID: 23133377
79. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2016.